Pazopanib does not bring remarkable improvement in patients with angiosarcoma
Author:
Affiliation:
1. Department of Dermatology; Hokkaido University Graduate School of Medicine; Sapporo Japan
2. Tokyo Metropolitan Cancer and Infectious Diseases Center; Komagome Hospital; Tokyo Japan
Publisher
Wiley
Subject
Dermatology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/1346-8138.13558/fullpdf
Reference13 articles.
1. Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study;Fujisawa;Br J Dermatol,2014
2. Angiosarcoma of the face and scalp, prognosis and treatment;Holden;Cancer,1987
3. Cutaneous angiosarcoma: a single-institution experience;Perez;Ann Surg Oncol,2013
4. ANGIOTAX-PLUS trial: a randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS);Penel;J Clin Oncol,2014
5. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled phase 3 trial;Graaf;Lancet,2012
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical course and vascular endothelial growth factor signaling system expression in maxillary angiosarcoma: A case report;Science Progress;2024-07
2. New molecular targets in canine hemangiosarcoma—Comparative review and future of the precision medicine;Veterinary and Comparative Oncology;2023-06-12
3. Primary cardiac sarcoma: demographics, genomic study correlation, and survival benefits of surgery with adjuvant therapy in U.S. population;Clinical Research in Cardiology;2023-05-29
4. Distinctive epidemiology and prognosis of de novo and secondary cutaneous angiosarcoma patients;International Journal of Dermatology;2023-04-17
5. OER‐073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma;Cancer;2022-08-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3